HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
HUTCHMED Announces US$608 million Divestment of Non-Core JointVenture
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to…
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms
November 28, 2024 05:30 ET | Source: HUTCHMED (China) Limited HONG KONG…